N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Patent metadata

Field	Value
Publication number	US-9725410-B2
Application number	US-201615286145-A
Country	US
Kind code	B2
Filing date	Oct 5, 2016
Priority date	Mar 17, 2006
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

The invention relates to N-hydroxysulfonamide derivatives that donate nitroxyl (HNO) under physiological conditions and are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure and ischemia/reperfusion injury. Novel N-hydroxysulfonamide derivatives release NHO at a controlled rate under physiological conditions, and the rate of HNO release is modulated by varying the nature and location of functional groups on the N-hydroxysulfonamide derivatives.

First claim

What is claimed:

1. A compound of formula (II):

or a pharmaceutically acceptable salt thereof, wherein:
R 1 is H;
R 2 is H, aralkyl, or heterocyclyl;
m and n are independently an integer from 0 to 1;
x is an integer from 0 to 4;
y is an integer from 0 to 3;
A is a cycloalkyl, heterocycloalkyl, aromatic, or heteroaromatic ring containing ring moieties Q 1 , Q 2 , Q 3 , and Q 4 , which are taken together with the carbon atoms at positions a and a′ to form ring A;
B is a cycloalkyl, heterocycloalkyl, aromatic, or heteroaromatic ring containing ring moieties Q 5 , Q 6 , Q 7 , and Q 8 , which are taken together with the carbon atoms at positions a and a′ to form ring B;
Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , Q 6 , Q 7 , and Q 8 are independently selected from the group consisting of C, CH, CH 2 , N, NR 10 , O, and S, provided that:
(1) when rings A and B together form naphthalene, x is an integer from 1 to 3 or y is the integer 2 or 3 and R 8 is other than Cl, or
(2) at least one of Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , Q 6 , Q 7 , and Q 8 is N, NR 10 , O, or S, or
(3) when rings A and B together form benzofuran, ring A is the oxygen containing ring and ring B is phenyl, or
(4) when one of rings A and B is phenyl and for the other of rings A and B at least one of Q 1 , Q 2 , Q 3 , and Q 4 is N or NR 10 , then ring B is phenyl;
each R 8 and R 9 is independently selected from halo, alkylsulfonyl, N-hydroxylsulfonamidyl, perhaloalkyl, nitro, aryl, cyano, alkoxy, perhaloalkoxy, alkyl, substituted aryloxy, alkyl sulfanyl, alkyl sulfinyl, heterocycloalkyl, substituted heterocycloalkyl, NH 2 , OH, C(O)OH, C(O)Oalkyl, NHC(O)alkylC(O)OH, C(O)NH 2 , NHC(O)alkylC(O)alkyl, NHC(O)alkenylC(O)OH, NHC(O)NH 2 , OalkylC(O)Oalkyl, NHC(O)alkyl, C(═N—OH)NH 2 , cycloalkoxy, cycloalkylsulfanyl, arylsulfanyl, and arylsulfinyl; and
R 10 is H, alkyl, acyl, or sulfonyl.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein A and B form a benzofuran.

3. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein x and y are 0.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein each R 8 and R 9 is independently selected from Cl, F, I, Br, SO 2 CH 3 , SO 2 NHOH, CF 3 , CH 3 , NO 2 , phenyl, CN, OCH 3 , OCF 3 , t-Bu, O-iPr, 4-nitrophenyloxy, SCH(CH 3 ) 2 , S(O)CH(CH 3 ) 2 , morpholino, N-methyl-piperazino, dimethylamino, piperidino, cyclohexyloxy, cyclopentylsulfanyl, phenyl sulfanyl, and phenyl sulfinyl.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 is H, benzyl, or tetrahydropyran-2-yl.

6. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 is H.

7. The compound of claim 4 or a pharmaceutically acceptable salt thereof of, wherein R 2 is H.

8. A compound which is:

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising:
the compound of claim 1 or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier.

10. A pharmaceutical composition comprising:
the compound of claim 7 or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier.

11. A method for modulating in vivo nitroxyl levels, treating a cardiovascular disease or condition, or treating heart failure, comprising administering to an individual in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

12. The method of claim 11 , wherein the heart failure is acute decompensated heart failure.

13. A method for modulating in vivo nitroxyl levels, treating a cardiovascular disease or condition, or treating heart failure, comprising administering to an individual in need thereof an effective amount of a compound of claim 7 or a pharmaceutically acceptable salt thereof.

14. The method of claim 13 , wherein the heart failure is acute decompensated heart failure.

15. A method for treating, preventing, delaying the onset of, or delaying the development of heart failure, comprising administering to an individual in need thereof an effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

16. A method for treating, preventing, delaying the onset of, or delaying the development of heart failure, comprising administering to an individual in need thereof an effective amount of a compound of claim 7 or a pharmaceutically acceptable salt thereof.

17. A method for modulating in vivo nitroxyl levels, treating a cardiovascular disease or condition, or treating heart failure, comprising administering to an individual in need thereof an effective amount of compound of formula (IIa) or a pharmaceutically acceptable salt thereof, wherein the compound of formula (IIa) is:

wherein:
R 1 is H;
R 2 is H, aralkyl, or heterocyclyl;
m and n are independently an integer from 0 to 1;
x is an integer from 0 to 4;
y is an integer from 0 to 3;
A is a cycloalkyl, heterocycloalkyl, aromatic, or heteroaromatic ring containing ring moieties Q 1 , Q 2 , Q 3 , and Q 4 , which are taken together with the carbon atoms at positions a and a′ to form ring A;
B is a cycloalkyl, heterocycloalkyl, aromatic, or heteroaromatic ring containing ring moieties Q 5 , Q 6 , Q 7 , and Q 8 , which are taken together with the carbon atoms at positions a and a′ to form ring B;
Q 1 , Q 2 , Q 3 , Q 4 , Q 5 , Q 6 , Q 7 , and Q 8 are independently selected from the group consisting of C, CH, CH 2 , N, NR 10 , O, and S, provided that either
(1) when rings A and B together form naphthalene, x is an integer from 1 to 3 or y is the integer 2 or 3 and R 8 is other than Cl, or
(2) at least one of Q 2 , Q 3 , Q 4 , Q 5 , Q 6 , Q 7 , and Q 8 is N, NR 10 , O, or S;
each R 8 and R 9 is independently selected from halo, alkylsulfonyl, N-hydroxylsulfonamidyl, perhaloalkyl, nitro, aryl, cyano, alkoxy, perhaloalkoxy, alkyl, substituted aryloxy, alkyl sulfanyl, alkyl sulfinyl, heterocycloalkyl, substituted heterocycloalkyl, NH 2 , OH, C(O)OH, C(O)Oalkyl, NHC(O)alkylC(O)OH, C(O)NH 2 , NHC(O)alkylC(O)alkyl, NHC(O)alkenylC(O)OH, NHC(O)NH 2 , OalkylC(O)Oalkyl, NHC(O)alkyl, C(═N—OH)NH 2 , cycloalkoxy, cycloalkylsulfanyl, arylsulfanyl, and arylsulfinyl; and
R 10 is H, alkyl, acyl, or sulfonyl.

18. The method of claim 17 , wherein R 2 is H and each R 8 and R 9 is independently selected from Cl, F, I, Br, SO 2 CH 3 , SO 2 NHOH, CF 3 , CH 3 , NO 2 , phenyl, CN, OCH 3 , OCF 3 , t-Bu, O-iPr, 4-nitrophenyloxy, SCH(CH 3 ) 2 , S(O)CH(CH 3 ) 2 , morpholino, N-methyl-piperazino, dimethylamino, piperidino, cyclohexyloxy, cyclopentylsulfanyl, phenyl sulfanyl, and phenyl sulfinyl.

19. The method of claim 18 , wherein the heart failure is acute decompensated heart failure.

20. The method of claim 17 , wherein the heart failure is acute decompensated heart failure.

Assignees

• Cardioxyl Pharmaceuticals Inc
• Univ Johns Hopkins
• Cardioxyl Pharmaceuticals Inc

Inventors

• Toscano John P
• Brookfield Frederick Arthur
• Cohen Andrew D
• Courtney Stephen Martin
• Frost Lisa Marie
• Kalish Vincent Jacob

Classifications

• A61P9/06

  Antiarrhythmics · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title